Time filter

Source Type

Giamarellos-Bourboulis E.J.,National and Kapodistrian University of Athens | Pyleris E.,Sismanogleion Athens General Hospital | Barbatzas C.,Sismanogleion Athens General Hospital | Pistiki A.,National and Kapodistrian University of Athens | Pimentel M.,Cedars Sinai Medical Center
BMC Gastroenterology | Year: 2016

Background: Current knowledge suggests that small intestinal overgrowth participates in the pathogenesis of irritable bowel syndrome. It is questionable if this association is modulated by intake of proton pump inhibitors (PPIs). Methods: In a prospective study, quantitative cultures of duodenal aspirates were performed for aerobic species in 897 consecutive patients undergoing upper GI tract endoscopy. SIBO was defined as equal to or more than 103 cfu/ml. The effect of PPI intake on the relationship between SIBO and IBS was the primary endpoint. Results: Analysis among patients without any history of PPI intake (n = 713) showed that odds ratio (OR) for IBS in the event of SIBO was 5.63 (3.73-8.51, p < 0.0001); this was 4.16 (1.91-9.06) when analysis was done among patients with history of PPI intake (n = 184, p: 0.498 between patients without and with PPI intake). Multiple logistic regression analysis found that factors independently associated with SIBO were age above or equal to 60 years (OR: 2.36), body mass index more than or equal to 22 kg/m2 (OR: 0.60), presence of IBS (OR: 6.29), type 2 diabetes mellitus (OR: 1.59) and gastritis (OR: 0.47). Conclusions: The association between IBS and SIBO was completely independent from PPI intake. Although gastritis was protective against SIBO, results show that PPI intake cannot prime SIBO. © 2016 The Author(s).


PubMed | Sismanogleion Athens General Hospital, National and Kapodistrian University of Athens and Cedars Sinai Medical Center
Type: Journal Article | Journal: BMC gastroenterology | Year: 2016

Current knowledge suggests that small intestinal overgrowth participates in the pathogenesis of irritable bowel syndrome. It is questionable if this association is modulated by intake of proton pump inhibitors (PPIs).In a prospective study, quantitative cultures of duodenal aspirates were performed for aerobic species in 897 consecutive patients undergoing upper GI tract endoscopy. SIBO was defined as equal to or more than 10(3)cfu/ml. The effect of PPI intake on the relationship between SIBO and IBS was the primary endpoint.Analysis among patients without any history of PPI intake (n=713) showed that odds ratio (OR) for IBS in the event of SIBO was 5.63 (3.73-8.51, p<0.0001); this was 4.16 (1.91-9.06) when analysis was done among patients with history of PPI intake (n=184, p: 0.498 between patients without and with PPI intake). Multiple logistic regression analysis found that factors independently associated with SIBO were age above or equal to 60years (OR: 2.36), body mass index more than or equal to 22kg/m(2) (OR: 0.60), presence of IBS (OR: 6.29), type 2 diabetes mellitus (OR: 1.59) and gastritis (OR: 0.47).The association between IBS and SIBO was completely independent from PPI intake. Although gastritis was protective against SIBO, results show that PPI intake cannot prime SIBO.

Loading Sismanogleion Athens General Hospital collaborators
Loading Sismanogleion Athens General Hospital collaborators